Related references
Note: Only part of the references are listed.Clinical effectiveness of oral antimicrobial therapy for acute pyelonephritis caused by extended-spectrum β-lactamase-producing Enterobacteriales
Si-Ho Kim et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2020)
Is Piperacillin-Tazobactam Effective for the Treatment of Pyelonephritis Caused by Extended-Spectrum β-Lactamase-Producing Organisms?
Sima L. Sharara et al.
CLINICAL INFECTIOUS DISEASES (2020)
Piperacillin-Tazobactam Versus Carbapenems for the Treatment of Nonbacteremic Urinary Tract Infections due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae
Jordan Brooke Tullos et al.
HOSPITAL PHARMACY (2020)
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance A Randomized Clinical Trial
Patrick N. A. Harris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Randomized controlled trial of piperacillintazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum betalactamase-producing Escherichia coli
Yu Bin Seo et al.
BMC INFECTIOUS DISEASES (2017)
The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections
Pranita D. Tamma et al.
CLINICAL INFECTIOUS DISEASES (2017)
A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae
Belen Gutierrez-Gutierrez et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Cefepime Therapy for Cefepime-Susceptible Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Bacteremia
Ruibin Wang et al.
OPEN FORUM INFECTIOUS DISEASES (2016)
Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae
Tat Ming Ng et al.
PLOS ONE (2016)
Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase Producing Enterobacteriaceae
Hadas Ofer-Friedman et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2015)
Comparable outcomes for β-lactam/β-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae
Patrick N. A. Harris et al.
ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL (2015)
Pharmacokinetics of ertapenem in outpatients with complicated urinary tract infections
Jian Zhou et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Cefepime Therapy for Monomicrobial Bacteremia Caused by Cefepime-Susceptible Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae: MIC Matters
Nan-Yao Lee et al.
CLINICAL INFECTIOUS DISEASES (2013)
Impact of Cefepime Therapy on Mortality among Patients with Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae and Escherichia coli
Teena Chopra et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
β-Lactam/β-Lactam Inhibitor Combinations for the Treatment of Bacteremia Due to Extended-Spectrum β-Lactamase-Producing Escherichia coli: A Post Hoc Analysis of Prospective Cohorts
Jesus Rodriguez-Bano et al.
CLINICAL INFECTIOUS DISEASES (2012)
Piperacillin-tazobactam as an initial empirical therapy of bacteremia caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae
Cheol-In Kang et al.
JOURNAL OF INFECTION (2012)
Evolution of extended-spectrum beta-lactamases by mutation
M. Gniadkowski
CLINICAL MICROBIOLOGY AND INFECTION (2008)
High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients
K Goethaert et al.
CLINICAL MICROBIOLOGY AND INFECTION (2006)
Extended-spectrum β-lactamases:: a clinical update
DL Paterson et al.
CLINICAL MICROBIOLOGY REVIEWS (2005)
Mechanisms of disease:: The new β-lactamases
GA Jacoby et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: A multicenter, evaluator-blind, prospective, randomized study
G Zanetti et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Share Paper
